Intervacc AB
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages… Read more
Intervacc AB (IVACC) - Net Assets
Latest net assets as of September 2025: Skr310.46 Million SEK
Based on the latest financial reports, Intervacc AB (IVACC) has net assets worth Skr310.46 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr329.23 Million) and total liabilities (Skr18.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr310.46 Million |
| % of Total Assets | 94.3% |
| Annual Growth Rate | 11.02% |
| 5-Year Change | -51.92% |
| 10-Year Change | 28.3% |
| Growth Volatility | 34.59 |
Intervacc AB - Net Assets Trend (2013–2024)
This chart illustrates how Intervacc AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Intervacc AB (2013–2024)
The table below shows the annual net assets of Intervacc AB from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr162.33 Million | -31.77% |
| 2023-12-31 | Skr237.93 Million | -4.89% |
| 2022-12-31 | Skr250.16 Million | -18.85% |
| 2021-12-31 | Skr308.25 Million | -8.70% |
| 2020-12-31 | Skr337.61 Million | +53.58% |
| 2019-12-31 | Skr219.82 Million | +15.44% |
| 2018-12-31 | Skr190.43 Million | +15.48% |
| 2017-12-31 | Skr164.90 Million | +26.66% |
| 2016-12-31 | Skr130.18 Million | +2.90% |
| 2015-12-31 | Skr126.52 Million | +23.83% |
| 2014-12-31 | Skr102.18 Million | +98.82% |
| 2013-12-31 | Skr51.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Intervacc AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17969197000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr15.15 Million | 9.33% |
| Other Comprehensive Income | Skr-186.10 Million | -114.64% |
| Other Components | Skr519.38 Million | 319.95% |
| Total Equity | Skr162.33 Million | 100.00% |
Intervacc AB Competitors by Market Cap
The table below lists competitors of Intervacc AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Surgepays Inc
NASDAQ:SURG
|
$13.22 Million |
|
Smart Digital Group Limited Ordinary Shares
NASDAQ:SDM
|
$13.22 Million |
|
Malmbergs Elektriska AB (publ)
ST:MEAB-B
|
$13.23 Million |
|
Kapston Services Limited
NSE:KAPSTON
|
$13.24 Million |
|
Koryo Electronics Co Ltd
TWO:8032
|
$13.22 Million |
|
Mestron Holdings
KLSE:0207
|
$13.22 Million |
|
Orient Bell Limited
NSE:ORIENTBELL
|
$13.22 Million |
|
LANSON-BCC INH. EO 10
F:GQ6
|
$13.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intervacc AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 237,931,000 to 162,329,000, a change of -75,602,000 (-31.8%).
- Net loss of 75,515,000 reduced equity.
- Other comprehensive income increased equity by 60,724,000.
- Other factors decreased equity by 60,811,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-75.52 Million | -46.52% |
| Other Comprehensive Income | Skr60.72 Million | +37.41% |
| Other Changes | Skr-60.81 Million | -37.46% |
| Total Change | Skr- | -31.77% |
Book Value vs Market Value Analysis
This analysis compares Intervacc AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.40x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Skr1.91 | Skr0.74 | x |
| 2014-12-31 | Skr3.79 | Skr0.74 | x |
| 2015-12-31 | Skr4.70 | Skr0.74 | x |
| 2016-12-31 | Skr9.79 | Skr0.74 | x |
| 2017-12-31 | Skr8.87 | Skr0.74 | x |
| 2018-12-31 | Skr5.42 | Skr0.74 | x |
| 2019-12-31 | Skr4.87 | Skr0.74 | x |
| 2020-12-31 | Skr6.24 | Skr0.74 | x |
| 2021-12-31 | Skr5.34 | Skr0.74 | x |
| 2022-12-31 | Skr4.32 | Skr0.74 | x |
| 2023-12-31 | Skr3.68 | Skr0.74 | x |
| 2024-12-31 | Skr1.84 | Skr0.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intervacc AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -640.66%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.15x
- Recent ROE (-46.52%) is below the historical average (-13.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -4.45% | -287.65% | 0.02x | 1.02x | Skr-7.42 Million |
| 2014 | 9.13% | 11.94% | 0.50x | 1.52x | Skr-894.00K |
| 2015 | 0.11% | 0.22% | 0.41x | 1.22x | Skr-12.51 Million |
| 2016 | -5.23% | -12.25% | 0.34x | 1.26x | Skr-19.83 Million |
| 2017 | -7.74% | -26.59% | 0.27x | 1.09x | Skr-29.26 Million |
| 2018 | -14.44% | -77.22% | 0.18x | 1.06x | Skr-46.53 Million |
| 2019 | -12.69% | -229.77% | 0.05x | 1.08x | Skr-49.87 Million |
| 2020 | -7.58% | -535.59% | 0.01x | 1.05x | Skr-59.36 Million |
| 2021 | -9.53% | -560.48% | 0.02x | 1.07x | Skr-60.20 Million |
| 2022 | -25.65% | -662.52% | 0.04x | 1.06x | Skr-89.17 Million |
| 2023 | -43.23% | -1283.24% | 0.03x | 1.09x | Skr-126.65 Million |
| 2024 | -46.52% | -640.66% | 0.06x | 1.15x | Skr-91.75 Million |
Industry Comparison
This section compares Intervacc AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intervacc AB (IVACC) | Skr310.46 Million | -4.45% | 0.06x | $13.22 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |